The Office of Hematology and Oncology Products at FDA has been renamed the Office of Oncologic Diseases—a move that includes an internal reorganization of divisions, as part of modernization plans approved in September 2019.
Norman E. Sharpless has returned to his previous role of NCI director earlier this week after serving as acting FDA commissioner since April 5.
Texans have approved an additional $3 billion in state funds for the Cancer Prevention and Research Institute of Texas, extending the institute's operations well past its sunset date in 2023.
David H. Thompson, a professor at the Department of Chemistry at Purdue University and a member of the Purdue Center for Cancer Research, is working on a better and faster way to produce drugs and eliminate shortages.
Lomustine, a.k.a. CCNU, is an old cancer drug.
President Donald Trump has announced his intention to nominate Stephen M. Hahn to the position of FDA commissioner Nov. 1.
The midterm elections of 1994 brought on political change that cost Dingell chairmanship of Energy & Commerce and Oversight and Investigations. He lost most of his staff, and there was no reason to continue oversight hearings of NSABP.
On a single day in March, Dr. Bernard Fisher of Pittsburgh, the country's pre-eminent breast cancer researcher, saw his own career crumble, and watched helplessly as the research organization he had led through unprecedented advances in the treatment of breast cancer was abruptly shut down.
Bernard Fisher had been in many a fight. He was, after all, an iconoclastic surgeon who had famously infuriated his colleagues by demonstrating that heroic surgeries in breast cancer do more harm than good.
The National Academy of Medicine announced the election of 90 regular members and 10 international members during its annual meeting Oct. 21.
